Jennison Associates LLC Savara Inc Transaction History

Jennison Associates LLC

$160 Billion
Q3 2024

A detailed history of Jennison Associates LLC transactions in Savara Inc stock. As of the latest transaction made, Jennison Associates LLC holds 6,732,776 shares of SVRA stock, worth $21.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

6,732,776

Previous 5,731,480 17.47%

Holding current value

$21.7 Million

Previous $23.1 Million 23.59%

% of portfolio

0.02%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$3.96 - $5.07 $3.97 Million - $5.08 Million	1,001,296 Added 17.47%	6,732,776 $28.5 Million
Q2 2024 Aug 05, 2024	SELL	$3.66 - $5.34 $11.4 Million - $16.6 Million	-3,110,491 Reduced 35.18%	5,731,480 $23.1 Million
Q1 2024 May 02, 2024	BUY	$4.19 - $5.59 $111,508 - $148,766	26,613 Added 0.3%	8,841,971 $44 Million
Q4 2023 Feb 01, 2024	BUY	$3.18 - $4.9 $15.7 Million - $24.2 Million	4,948,596 Added 127.98%	8,815,358 $41.4 Million
Q3 2023 Oct 31, 2023	BUY	$2.97 - $3.88 $3.54 Million - $4.63 Million	1,192,730 Added 44.6%	3,866,762 $14.6 Million
Q2 2023 Aug 03, 2023	BUY	$1.69 - $3.24 $4.52 Million - $8.66 Million	2,674,032 New	2,674,032 $8.53 Million
Q3 2018 Nov 08, 2018	SELL	$10.49 - $12.87 $8.33 Million - $10.2 Million	-794,234 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$8.55 - $13.76 $90,732 - $146,021	10,612 Added 1.35%	794,234 $8.99 Million
Q1 2018 Apr 20, 2018	BUY	$8.99 - $14.95 $610,888 - $1.02 Million	67,952 Added 9.49%	783,622 $7.21 Million
Q4 2017 Jan 25, 2018	BUY	$8.26 - $16.76 $5.91 Million - $12 Million	715,670	715,670 $10.6 Million

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $368M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account

Jennison Associates LLC Savara Inc Transaction History